drugset / Trial / NCT00293319
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
Phase 2
Completed
164 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Radioactive drugs, such as 131 I-MIBG, may carry radiation directly to tumor cells and not harm normal cells. PURPOSE: This phase II trial is studying how well 131 I-MIBG works in treating patients with refractory or relapsed neuroblastoma.
Timeline
- Start
- 2005-04
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |